Concepedia

Scott R. Daigle

SR

Statistics

Publications

33

Citations

4.4K

H-Index

24

Active since

2010

Affiliations

Epizyme (United States)(Current)

Memorial Sloan Kettering Cancer Center

Dana-Farber Cancer Institute

The University of Texas MD Anderson Cancer Center

University of Colorado Denver

Scott R. Daigle is an author at Epizyme (United States) specializing in medicine, molecular oncology, and oncology.

Publications per year

2010–2024

33

Publications

33

Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor

Scott R. Daigle, Edward J. Olhava, Carly A. Therkelsen et al. · Cancer Cell · 2011 · 934 citations · Full text

, , +10

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

Scott R. Daigle, Edward J. Olhava, Carly A. Therkelsen et al. · Blood · 2013 · 725 citations · Full text

, , +11

Ivosidenib and Azacitidine in <i>IDH1</i> -Mutated Acute Myeloid Leukemia

Pau Montesinos, Christian Récher, Susana Vives et al. · New England Journal of Medicine · 2022 · 483 citations · Full text

, , +10

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia

Eytan M. Stein, Guillermo Garcia‐Manero, David A. Rizzieri et al. · Blood · 2018 · 457 citations · Full text

, , +10

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

Courtney D. DiNardo, Anthony S. Stein, Eytan M. Stein et al. · Journal of Clinical Oncology · 2020 · 174 citations · Full text

, , +16

1–5 of 33